The renin–angiotensin–aldosterone system (RAAS) is central to the pathogenesis of heart
failure (HF) and medications inhibiting RAAS are critical. Angiotensin-converting enzyme …

Almost 5 million individuals in the United States have chronic heart failure (HF), which is
increasing in prevalence. Angiotensin‐converting enzyme (ACE) inhibitors are standard …

EDITOR SUMMARYBackground: The role of angiotensin-receptor blockers (ARBs) in the
therapy of chronic heart failure (CHF) has not been clarified. There are no large placebo …

The prevalence of heart failure (HF) is high and still on the rise. In 2004, an estimated 5.2
million adults in the United States carried the diagnosis of HF with a mortality rate of> 19 …

Valsartan reduces morbidity in people with heart failure receiving a low dose of ACE inhibitor and
no beta-blocker. Commentary. - Abstract - Europe PMC Sign in | Create an account …

Inhibiting the synthesis of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE)
inhibitor treatment has long been established as the recommended therapy for heart failure …

Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …

The effects of ACE-inhibitors have been documented extensively during the last 15 years.
They offer wide benefits to patients with cardiovascular disease. Their effects are most …

Angiotensin‐converting enzyme (ACE) inhibitors have a central role in the management of
heart failure, reflecting the contribution of the renin‐angiotensin‐aldosterone system to the …

Study Objective. To examine the class effect of angiotensin II receptor blockers (ARBs) on
mortality in patients with heart failure who were aged 65 years or older. Design …